Obesity management has entered a new era with highly effective obesity management medications (OMMs), reigniting discussions on the relative roles of lifestyle intervention and pharmacotherapy in long-term obesity management.¹ At the 2^nd Malaysian Obesity Society (MYOS) National Obesity Scientific Conference (NOSC) 2026, Professor Dr. Winnie Chee Siew Swee from the IMU University and Dr. Alexander Tan Tong Boon from Sunway Medical Centre, Malaysia, debated whether lifestyle intervention should remain central or pharmacotherapy should represent the future direction of treatment.¹ Both experts presented contrasting perspectives on prioritization strategies in addressing the growing obesity burden.¹

Prof. Winnie supported the motion that lifestyle intervention should remain central.¹ She emphasized that all approved OMMs are indicated for use alongside dietary modification, physical activity, and behavioral modifications.¹ Major clinical trials of glucagon-like peptide-1 (GLP-1)-based therapies, such as the Semaglutide Treatment Effect in People with obesity (STEP) and Study of Tirzepatide in Participants With Obesity or Overweight (SURMOUNT) trials, incorporated structured lifestyle programs as a mandatory background component, indicating that observed efficacy reflects combined therapy rather than pharmacotherapy alone.^2,3 Evidence further shows that intensive lifestyle intervention acts as an amplifier of pharmacotherapy to augment weight loss.^1,4 It may also attenuate weight regain following discontinuation of pharmacotherapy, as sustained lifestyle intervention is associated with reduced post-treatment weight regain and improved long-term weight maintenance.^1,5

Prof. Winnie also highlighted real-world evidence of substantial discontinuation rates for anti-obesity medications driven by cost, availability, and tolerability.⁶ In such situations, sustainable behavioral change becomes essential for maintaining weight reduction, as weight regain occurs most slowly among individuals with sustained lifestyle intervention.¹ She also emphasized that rapid pharmacotherapy-driven weight loss may increase the risk of lean mass loss and micronutrient deficiencies, particularly when appetite suppression significantly reduces dietary intake without nutritional supervision.⁷ Structured dietary guidance and behavioral support, therefore, remain essential for safe and effective weight management.¹

Beyond weight reduction alone, lifestyle intervention confers broader and durable health benefits, including improvements in metabolic parameters, physical function, and psychological wellbeing.⁸ Importantly, behavioral modification fosters lasting habits that persist beyond pharmacological therapy.⁹ Prof. Winnie concluded that pharmacotherapy should be viewed as a facilitator of lifestyle change rather than a replacement for it.¹ While medications may reduce appetite and lower barriers to behavioral change, long-term success ultimately depends on sustained lifestyle modification.¹

Dr. Alexander, however, framed his argument from a population health perspective, emphasizing pharmacotherapy as the future direction of obesity management due to its scalability and ability to deliver meaningful outcomes at scale.¹ Obesity affects a large and growing population, with 54.4% of adults classified as overweight or obese.¹⁰ From a health policy standpoint, he highlighted resource allocation challenges between expanding lifestyle services and investing in pharmacological therapies.¹ This highlights a fundamental trade-off between scalability and resource intensity in obesity management strategies.¹ Intensive lifestyle counseling requires multidisciplinary professionals such as dietitians, psychologists, and exercise specialists, whose availability is limited relative to the magnitude of the obesity epidemic.¹ This workforce constraint restricts the reach of lifestyle-based interventions.¹ In contrast, pharmacotherapy can be deployed in a reproducible manner at scale, delivering clinically meaningful weight reduction across large patient populations.¹

Contemporary OMMs have also demonstrated substantial and consistent weight loss in clinical trials, with the majority of patients achieving clinically meaningful reductions in body weight.^3,11,12 Dr. Alexander emphasized that obesity should be recognized and treated as a chronic disease driving multiple downstream conditions, including type 2 diabetes, cardiovascular disease, and chronic kidney disease.¹ Beyond weight reductions, he therefore emphasized that treatment priorities should extend beyond surrogate metabolic markers such as glycated hemoglobin or lipid levels to clinically meaningful outcomes, including reduced cardiovascular events, prevention of renal failure, and improved survival, as well as broader metabolic and cardio-renal benefits.¹

Dr. Alexander also highlighted that obesity is a highly complex chronic disease influenced by multiple biological, environmental, psychological, and socioeconomic determinants.¹ Modern food environments, aggressive food marketing, sedentary lifestyles, and genetic susceptibility collectively contribute to disease development.¹ In this context, reliance on behavioral change alone may not adequately address the multifactorial drivers of obesity.¹ From this perspective, he argued that obesity should be managed similarly to other chronic diseases, such as hypertension or diabetes, where lifestyle modification is recommended but pharmacotherapy remains central to long-term disease control.¹

The debate reflects two complementary perspectives on obesity care.¹ Prof. Winnie emphasized the enduring importance of lifestyle intervention as the foundation for sustainable weight management and long-term health outcomes.¹ Dr. Alexander highlighted the growing role of pharmacotherapy as a scalable and biologically effective strategy for addressing obesity at a population level.¹ Together, these perspectives illustrate the need for integrated approaches that combine behavioral and pharmacological strategies for comprehensive obesity management.¹